Table 2.

Prognostic factors for EPS in patients starting PD

	Standard analysis				Competing risks analysis
	Unadjusted		Adjusted		Unadjusted		Adjusted
	HR (95% CI)	P-value	HR (95% CI)	P-value	SHR (95% CI)	P-value	SHR (95% CI)	P-value
Age (10 years)	0.932 (0.81–1.07)	0.324	0.899 (0.78–1.04)	0.146	0.724 (0.64–0.82)	<0.001	0.771 (0.68–0.88)	<0.001
Sex, male	0.896 (0.59–1.35)	0.602	1.024 (0.67–1.56)	0.911	0.871 (0.59–1.29)	0.491	1.171 (0.78–1.75)	0.442
Diabetes	0.935 (0.58–1.51)	0.784	1.319 (0.75–2.33)	0.338	0.500 (0.31–0.80)	0.004	0.854 (0.49–1.48)	0.574
High-risk PRD	0.770 (0.51–1.17)	0.223	0.707 (0.43–1.16)	0.170	0.465 (0.31–0.69)	<0.001	0.714 (0.44–1.15)	0.166
Duration of PD (per year)a	1.168 (1.11–1.23) 0.985 (0.98–0.99)	<0.001	1.172 (1.11–1.23) 0.984 (0.98–0.99)	<0.001	1.448 (1.35–1.55)	<0.001	1.415 (1.32–1.52)	<0.001

HR, cause-specific hazard ratio; PRD, primary renal disease; SHR, subdistribution hazard ratio.

^aFractional polynomial terms with powers 2 and 3 were selected to model the non-linearity of the duration of PD in the standard analysis.